'Recombinant dna advisory committee' presentation slideshows

Recombinant DNA Technology

Recombinant DNA Technology. Recombinant DNA Technology. T echnique that allows DNA to be combined from different sources DNA code universal Foundation of genetic engineering. Review. What are enzymes? What function do they serve? What makes up the DNA sequence?

1.29k views • 45 slides

The Regulation of Genetic Modifications

736 views • 44 slides

Recombinant DNA Technology

Recombinant DNA Technology. Review. What are enzymes? What function do they serve? What makes up the DNA sequence? How is the genetic code determined in an organism? . Recombinant DNA Technology. http://www.youtube.com/watch?v=x2jUMG2E-ic. Discovery of restriction enzymes.

797 views • 41 slides

Introduction

Introduction.

411 views • 35 slides

Plasmids and Vectors

Plasmids and Vectors. Instructor Supplement to pGlo Bacterial Transformation. Promotor Site. Origin of Replication. Antibiotic Resistance Gene. Multiple Cloning Site. A more detailed look at plasmids. Cloning into a Plasmid. Asilomar Conference.

1.53k views • 33 slides

Contemporary Challenges to the Immune System

Contemporary Challenges to the Immune System. Challenges of the immune system. Outside. Infection with microbe A. Vaccine. Infection with microbe B. Allergen -> allergy. Peptide drugs. Time. Creation of self. Creation of an immune system/ Tolerance to self. Autoimmunity

391 views • 32 slides

ROLE OF THE INSTITUTIONAL BIOSAFETY COMMITTEE

ROLE OF THE INSTITUTIONAL BIOSAFETY COMMITTEE. Bob Hashimoto The University of Kentucky November 22, 2002. INTRODUCTION.

1.79k views • 30 slides

Outline

Outline. Introduction to the National Institutes of Health Office of Biotechnology Activities History and Evolution of IBCs: Asilomar to the Present Overview of the Current NIH Guidelines for Research Involving Recombinant DNA Molecules Requirements for IBCs in the NIH Guidelines

280 views • 21 slides

Hatch-Waxman Revisited

Hatch-Waxman Revisited. Allows patent owners to recover time spent in clinical trials and FDA regulatory review Specifically, pioneer companies are granted an extra half-day of patent life for every day spent in clinical trials and an extra day for every day spent in FDA review period

495 views • 16 slides

The Select Agent Laboratory:

The Select Agent Laboratory:. at the intersection of research, preparedness and safety Nancy Connell,PhD Professor and Vice-chair for Research Department of Medicine UMDNJ-New Jersey Medical School Director, UMDNJ Center for BioDefense. Safety- regulations training inspections

212 views • 13 slides